NIH-funded study identifies gene variant as potential drug target
Defying the odds, an individual at high risk for early-onset Alzheimer’s disease remained dementia-free for many years beyond what was anticipated. A study funded in part by the National Institute on Aging (NIA), part of the National Institutes of Health, led researchers to suggest that a gene variant may be the key, perhaps providing a new direction toward developing a treatment.
The research focused on the case of a woman who carried a gene mutation known to cause early-onset Alzheimer’s. However, she did not develop signs of the disease until her seventies, nearly three decades after her expected age of onset. The researchers suspect that she may have been protected because in addition to the gene mutation causing early-onset Alzheimer’s in her family, she also had two copies of the APOE3 Christchurch (APOE3ch) gene variant. Findings of this case study as published in Nature Medicine suggest that two copies of the APOE3ch variant, named after Christchurch, New Zealand where it was first identified, may protect against Alzheimer’s.
“Sometimes close analysis of a single case can lead to discovery that could have broad implications for the field,” said NIA Director Richard J. Hodes, M.D. “We are encouraged that as part of our wide array of studies, this research in the unique genetic makeup of an exceptional individual can reveal helpful information.”
Early-onset Alzheimer’s disease is rare, representing less than 10% of all people who have Alzheimer’s. It typically occurs between a person’s 30s to mid-60s. Risk for both early- and late-onset Alzheimer’s disease is affected by genetic factors.
For the study, researchers led by investigators at Massachusetts General Hospital, Boston, in collaboration with the University of Antioquia, Medellin, Colombia, Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, and Banner Alzheimer’s Institute, Phoenix, looked at genetic data from a Colombian family with more than 6,000 living members. Family members who carry a rare gene mutation called Presenilin 1 (PSEN1) E280A, have a 99.9% risk of developing early-onset Alzheimer’s disease.
The researchers confirmed that the woman in this case carried the PSEN1 E280A mutation, which caused early-onset Alzheimer’s in her other family members. However, she also had two copies of the APOE3ch gene variant, while no other affected family member carried two copies of this variant. Affected family members develop Alzheimer’s in their 40s, but she remained disease free until her 70s. Imaging tests showed that the woman had only minor neurodegeneration. She did have large amounts of amyloid protein deposits, a hallmark of Alzheimer’s disease, in her brain. But the amount of tau tangles, another hallmark of the disease, and the one more correlated with how thinking and memory are affected, was relatively low.
Experiments as part of the study showed that the APOE3ch variant may reduce the ability of APOE to bind to certain sugars called heparan sulphate proteoglycans (HSPG). APOE binding to HSPG has been implicated as one mechanism that may contribute to the amyloid and tau protein deposits that destroy the brain. The research suggests that a drug or gene therapy that could reduce APOE and HSPG binding has the potential to be a new way to treat or prevent Alzheimer’s disease.
The Latest on: Alzheimer’s
via Google News
The Latest on: Alzheimer’s
- COVID-19 tips among free June webinars to help Alzheimer’s caregiverson June 6, 2020 at 4:00 am
Helping Alzheimer’s caregivers prepare for the challenges ahead of them – and cope with the changes brought by the coronavirus pandemic – is the goal of a series ...
- Alzheimer’s Association Wyoming Chapter urges Cheyenne to fund senior centeron June 6, 2020 at 4:00 am
The Wyoming Chapter of the Alzheimer’s Association is urging the Cheyenne City Council to reconsider the complete defunding in the city’s 2021 budget of the Laramie County Senior ...
- Alzheimer’s Disease: Epidemiology Forecast to 2028on June 5, 2020 at 9:41 pm
Reportlinker.com announces the release of the report "Alzheimer’s Disease: Epidemiology Forecast to 2028" - AD is the most common type of dementia (Centers for Disease Control and Prevention, 2019).
- Intranasal delivery of MSCs provides hope for treating Alzheimer's diseaseon June 5, 2020 at 4:21 am
In the search for a cure for Alzheimer's disease, mesenchymal stem cells and their derived extracellular vesicles (MSC-EVs) offer much promise, thanks to their protective and anti-inflammatory ...
- Alzheimer’s disease: we designed an antibody to detect toxic particles in the brainon June 4, 2020 at 7:50 am
We designed an antibody that is able to detect the toxic brain particles thought to cause Alzheimer’s. The memory loss and cognitive impairment caused by Alzheimer’s disease can be traced back to to a ...
- Seattle biotech startup Athira raises $85M to develop therapies for Alzheimer’s and Parkinson’son June 4, 2020 at 4:36 am
The foundation of Athira Pharma began while Leen Kawas was earning her Ph.D. in molecular pharmacology at Washington State University nearly a decade ago. Fast forward to today and the Seattle ...
- Seattle biotech firm scores $85 million for work on Alzheimer’s drug, despite hurdles of coronavirus pandemicon June 4, 2020 at 4:30 am
Athira Pharma's small-molecule drug is designed to specifically enhance the activity of a naturally occurring brain mechanism that has the potential to restore neuron health and brain function.
- Spontaneous MEG activity of the cerebral cortex during eyes closed and open discriminates Alzheimer’s disease from cognitively normal older adultson June 4, 2020 at 2:11 am
This study aimed to examine whether magnetoencephalography (MEG) is useful to detect early stage Alzheimer’s disease (AD). We analyzed MEG data from the early stage AD group (n = 20; 6 with mild ...
- What You Can Do Today to Help Prevent Alzheimer'son June 3, 2020 at 12:05 pm
The exact cause of Alzheimer's remains elusive, but that doesn't mean we're helpless to prevent it. Of course there's no foolproof, one-size-fits-all secret to Alzheimer's prevention — but experts say ...
- These Colombian Scientists Revealed Alzheimer’s Secrets By Turning Umbilical Cord Tissue Into Brain Cellson June 3, 2020 at 7:05 am
A husband and wife team of Colombian scientists have observed Alzheimer's precursor molecules in cells taken from newborns – a boon for research into the earliest stages of a disease that doesn’t ...
via Bing News